Document is current

Any future updates will be listed below

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Crossref DOI link: https://doi.org/10.1186/s12885-016-2736-9

Published Online: 2016-08-31

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark